|
The Therapeutic Vaccine Potential of MIS416 Adjuvant
|
|
|
| By
Gill A. Webster, PhD
,
Frank B. Gelder, PhD
|
|
|
|
This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
|
|
|
|
An Alternative to the Scale-up and Distribution of Pandemic Flu Vaccine
|
|
|
| By
James M. Robinson
|
|
|
|
With virus-based production, vaccines can be available in 10-12 weeks.
|
|
|
|
Advances in Single-Shot Vaccine Development
|
|
|
| By
Bas Kremer, PhD
,
Rianne Roukema
,
Leo de Leede
|
|
|
|
The disadvantages of the traditional vaccine regime (prime plus boost) have spurred the development of single-shot vaccines. This article describes the development and manufacture of a prototype single-shot vaccine that uses microspheres made from cross-linked modified dextran polymers for controlled release of the antigen.
|
|
|
